Overall responses with coordinated pembrolizumab and high dose IL-2 (5-in-a-row schedule) for therapy of metastatic clear cell renal cancer: A single center, single arm trial.
Jonathan Alexander Chatzkel(University of Florida), Mayer Fishman(Moffitt Cancer Center), Sarah K Hart(Moffitt Cancer Center), Steven P. Ludlow(Healthwise), Yazmin Rodriguez(Moffitt Cancer Center), Michael J. Schell(University of Bonn), Kristina Lombardi(Moffitt Cancer Center), Jennifer Rembisz(Moffitt Cancer Center), Cortlin Croft(Moffitt Cancer Center), Elaine C. Johnson(Oregon Health & Science University), Jiqiang Yao(Moffitt Cancer Center), Jingsong Zhang(Moffitt Cancer Center), Tina Terraciano(Moffitt Cancer Center), Yesenia Artigas(Moffitt Cancer Center), Jennifer Swank(Moffitt Cancer Center)
Cited by 8
Related Papers
Comprehensive genomic characterization defines human glioblastoma genes and core pathways
|Nature|2008|7.8k
Somatic mutations affect key pathways in lung adenocarcinoma
|Nature|2008|2.8k
Efficacy and Safety of Durvalumab in Locally Advanced or Metastatic Urothelial Carcinoma
|JAMA Oncology|2017|846
Rucaparib in Men With Metastatic Castration-Resistant Prostate Cancer Harboring a<i>BRCA1</i>or<i>BRCA2</i>Gene Alteration
|Journal of Clinical Oncology|2020|676
A Rat Model of Chronic Pressure-induced Optic Nerve Damage
|Experimental Eye Research|1997|526